Drug intelligence / Profile preview

OHB-211

Development stage: Discontinued
Lead developer: Oak Hill Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

OHB-211 is a monoclonal antibody drug candidate that acts as an antagonist of CD32B (also known as the low affinity immunoglobulin gamma Fc region receptor II-b). It was initially developed by SuppreMol GmbH and later associated with Oak Hill Bio. The drug was designed for the treatment of immune system diseases, specifically targeting autoimmune diseases. Its mechanism involves blocking CD32B to modulate immune responses. Development of OHB-211 has been discontinued at the preclinical stage and it is not approved or marketed in any country[1][2].

Targets

FCGR2B (Fc gamma receptor IIB)

Beyond the preview

Go deeper on OHB-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OHB-211.